Heron Therapeutics announced that the U.S. FDA has approved the company’s Prior Approval Supplement Application for ZYNRELEF extended-release solution VAN. The VAN will replace the current vented vial spike and has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF’s withdrawal time down to between twenty and forty-five seconds. The user-friendly “container-like” design of the VAN may enhance the safe use of ZYNRELEF, increase adoption, and improve the preparation process. The VAN is expected to launch in Q4 of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- Heron Therapeutics names Brett Fleshman as Chief Business Officer
- Heron reaffirms FY24 revenue view $138.0M-$158.0M, consensus $147.8M
- Heron Therapeutics reports Q2 EPS (6c), consensus (4c)
- Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
- Is HRTX a Buy, Before Earnings?